Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis
- PMID: 24890070
- PMCID: PMC4102290
- DOI: 10.1002/wps.20130
Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis
Abstract
Antipsychotic drugs such as clozapine and olanzapine are associated with an increased risk for type 2 diabetes, but relatively little is known about the relationship between risk factors for type 2 diabetes established in the general population and type 2 diabetes in people with psychosis. We estimated the prevalence of established risk factors and their association with type 2 diabetes in a nationally representative sample of people with an ICD-10 psychosis (N=1642) who gave a fasting blood sample (N=1155). Logistic regression was used to summarize associations adjusted for age and sex. In this sample, whose mean duration of psychosis was 14.7 years, 12.1% (13.1% of women and 11.5% of men) had type 2 diabetes at age 18-64 years based on current fasting blood glucose levels or treatment with a hypoglycaemic drug. Risk was greatly increased in young adults compared with the general population and peaked in middle age. Risk factors in the general population were common in people with psychosis and strongly associated with type 2 diabetes in those people. Treatment with clozapine was associated with an increased risk and treatment with olanzapine with a decreased risk for type 2 diabetes. The development of diabetes or pre-diabetes may therefore influence the likelihood of treatment with olanzapine over time. The strongest predictors of type 2 diabetes in a multivariate model were a body mass index of at least 40 and treated hypercholesterolemia, followed by a body mass index between 35 and 39.9, a family history of diabetes and treated hypertension. There was minimal to no confounding of the association between type 2 diabetes and current clozapine or olanzapine treatment, but neither association remained significant after adjustment for other predictors. Longitudinal relationships among predictors are likely to be complex, and previous antipsychotic drug treatment may at least partly explain risks associated with severe obesity, dyslipidemia and hypertension. A focus on weight loss is warranted in people with psychosis, but prevention strategies for type 2 diabetes should be broadened to include those with emerging dyslipidemia, hypertension and a family history of diabetes.
Keywords: Type 2 diabetes; body mass index; clozapine; hypercholesterolemia; hypertension; olanzapine; psychosis; risk factors.
Copyright © 2014 World Psychiatric Association.
Similar articles
-
Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study.Lancet Psychiatry. 2015 Dec;2(12):1092-8. doi: 10.1016/S2215-0366(15)00276-X. Epub 2015 Oct 22. Lancet Psychiatry. 2015. PMID: 26477242
-
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Arch Gen Psychiatry. 2005 Jan;62(1):19-28. doi: 10.1001/archpsyc.62.1.19. Arch Gen Psychiatry. 2005. PMID: 15630069
-
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.J Clin Psychiatry. 2002 Oct;63(10):920-30. doi: 10.4088/jcp.v63n1010. J Clin Psychiatry. 2002. PMID: 12416602
-
Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.Adv Ther. 2021 May;38(5):2491-2512. doi: 10.1007/s12325-021-01689-8. Epub 2021 Apr 7. Adv Ther. 2021. PMID: 33826090 Free PMC article.
-
[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. doi: 10.1016/s0013-7006(05)82412-1. Encephale. 2005. PMID: 16389718 Review. French.
Cited by
-
Assessment of Antipsychotic Medications on Social Media: Machine Learning Study.Front Psychiatry. 2021 Nov 18;12:737684. doi: 10.3389/fpsyt.2021.737684. eCollection 2021. Front Psychiatry. 2021. PMID: 34867531 Free PMC article.
-
Amisulpride as the antipsychotic of choice in severe psychotic disorder with comorbid impaired glucose tolerance.Ind Psychiatry J. 2024 Jan-Jun;33(1):168-171. doi: 10.4103/ipj.ipj_133_23. Epub 2024 Feb 9. Ind Psychiatry J. 2024. PMID: 38853806 Free PMC article.
-
Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis.Schizophr Bull. 2016 Sep;42(5):1280-9. doi: 10.1093/schbul/sbw027. Epub 2016 May 5. Schizophr Bull. 2016. PMID: 27150636 Free PMC article.
-
Undiagnosed Diabetes Mellitus and Associated Factors among Psychiatric Patients Receiving Antipsychotic Drugs at The University of Gondar Hospital, Northwest Ethiopia.Ethiop J Health Sci. 2018 Jan;28(1):3-10. doi: 10.4314/ejhs.v28i1.2. Ethiop J Health Sci. 2018. PMID: 29622902 Free PMC article.
-
Comorbid Diabetes and Depression in a National Sample of Adults With Psychosis.Schizophr Bull. 2018 Jan 13;44(1):84-92. doi: 10.1093/schbul/sbw166. Schizophr Bull. 2018. PMID: 27872261 Free PMC article.
References
-
- Rouillon F, Sorbara F. Schizophrenia and diabetes: epidemiological data. Eur Psychiatry. 2005;20(Suppl. 4):S345–8. - PubMed
-
- Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry. 2004;184(Suppl. 47):S64–6. - PubMed
-
- Meltzer HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin. 1997;14:1–20. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources